Committee Unblinds Phase III Zytiga Study
USPSTF and ACS Recommend Less Frequent Cervical Cancer Screenings and Pap Smears
Tobacco Control and Prevention Saved 795,000 Lives Between 1975-2000, Study Shows
Five-year Childhood ALL Survival Increased To 90.4 Percent by 2005
Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit
Study: Freezing Secondary Tumors Helpful in Metastatic Breast Cancer
Women Who Received CMF Chemotherapy Score Lower On Cognitive Skill Exams
Three Studies Demonstrate Oncotype DX Test Effectiveness
ACG Highlights Link Between Obesity and Colorectal Cancer
Olaparib Study Demonstrates No Changes In Overall Survival
Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study
Trials Approved by NCI CTEP For the Month of March
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - CBER Director Vinay Prasad dared to “say no to drugs”
- J. Craig Venter’s work was foundational to cancer advancement of the past 25 years
- Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
